Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a 30 mg oral tablet for oral use. It is indicated for the prevention of cerebral vasospasm following subarachnoid hemorrhage, helping to maintain cerebral blood flow in affected patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance for EU‑origin medicines and supporting timely delivery across global markets.

Nimotop (nimodipine) is a cerebral vasodilator used in the management of vascular complications after subarachnoid hemorrhage.

- Subarachnoid hemorrhage: prevention of cerebral vasospasm to reduce the risk of delayed ischemic neurological deficits. - Aneurysmal SAH: supports maintenance of cerebral perfusion during the acute phase. - Neurocritical care after SAH: adjunct therapy to improve cerebral blood flow and limit secondary brain injury.

Nimotop may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported during early therapy. - Hypotension: transient lowering of blood pressure, especially when standing. - Nausea or vomiting: gastrointestinal discomfort that may resolve with continued use. - Flushing or warmth: sensation of heat, usually on the face or neck. - Dizziness or light‑headedness: related to blood pressure changes. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial ischemia or infarction: rare cardiac events linked to excessive vasodilation. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or anaphylaxis in hypersensitive individuals. - Seizures: infrequent neurologic events reported in isolated cases.

Before initiating Nimotop, clinicians should consider several safety measures.

- Blood pressure monitoring: check for hypotension, especially in patients on other antihypertensives. - CYP3A4 inhibitors: avoid strong inhibitors (e.g., ketoconazole) that may raise nimodipine levels. - Hepatic impairment: use with caution and adjust therapy if liver function is compromised. - Abrupt discontinuation: do not stop suddenly without medical guidance to prevent rebound vasospasm. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nimotop can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity. - Concomitant antihypertensives: additive hypotensive effect. - Grapefruit juice: can elevate nimodipine exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other calcium channel blockers: potential for enhanced cardiovascular effects. - Diuretics: may affect electrolyte balance and blood pressure stability.